Compare FRST & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | QTTB |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 450.1M |
| IPO Year | 2006 | 2018 |
| Metric | FRST | QTTB |
|---|---|---|
| Price | $16.29 | $15.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 158.2K | ★ 451.9K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | 136.78 |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $24.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $1.62 |
| 52 Week High | $16.88 | $23.57 |
| Indicator | FRST | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 52.26 |
| Support Level | $15.21 | $14.44 |
| Resistance Level | $16.39 | $16.78 |
| Average True Range (ATR) | 0.29 | 0.93 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 51.05 | 35.99 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).